Save This Listing
Stumble It
Reporter Account  Create New Account  Login!
Search :
QUICK LINKS : Art & Entertainment Automotive Blogging & Social Media Business Computer Design Education Environment Events / Trade Shows  
Post Your Story for FREE!
forpressrelease.com
Platform for Startups
forpressrelease.com
Promote Your Events
forpressrelease.com
Increase Sales in Just 69 secs!
forpressrelease.com
For Press Release Writing
forpressrelease.com
 
 
 
Press Release Details    
Add to Favorites  Mail to a Friend Print Page   Share This News Rate
Save This Listing     Stumble It          
173

Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China

This is first time in history, Chinese pharmaceutical authorities officially issued a guidance on international multi-center clinical trials of drugs in China, which has begun to be implemented on March 1, 2015. The guidance provides an opportunity to reduce risk from the examination uncertainty and approval delays to eat up your time and energy to achieve a successful entry into such a lucrative drug market, and to avoid trouble for your business smoothly in China. The overseas and multinational pharmaceutical manufacturers must be compliance with the latest regulations.
Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China provided a comprehensive and thorough knowledge of the Guidance on international multi-center clinical trials of drugs in China and guide you use the Chinese trial venues to keep drug development lean and to smoothly operate in China.

Browse more info at https://www.themarketreports.com/report/latest-regulations-on-pharmaceutical-international-multi-center-clinical-trials-in-chinaExecutive Summary
Summary
China’s healthcare market is indispensable for overseas and multinational pharmaceutical companies, but Chinese regulations on pharmaceutical clinical trials are undergoing sharp changes. This is first time in history, Chinese pharmaceutical authorities officially issued guidance on international multi-center clinical trials of drugs in China, which has begun to be implemented on March 1, 2015. To enter into Chinese lucrative drug market, the overseas and multinational pharmaceutical manufacturers must be compliance with this latest regulations. How do respond such challenges? The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and thorough knowledge of the Guidance on Chinese international multi-center clinical trials of drugs, and must be compliance with the latest regulations.
Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China provided a comprehensive and thorough knowledge of the Guidance on international multi-center clinical trials of drugs in China and guide you use the Chinese trial venues to keep drug development lean and to smoothly operate in China step by step.

Ask your query related to this report at https://www.themarketreports.com/report/ask-your-query/1255
The organizations of this guidebook are arranged as follows. Chapter 2 provides an overview of the Chinese regulatory authorities -- China Food and Drug Administration (CFDA) being responsible for application and approval for international multi-center clinical trials of drug registration to give the direction of gateway for application for approval of clinical trial of imported overseas drug registration. Chapter 3 elaborates the background of promulgating Guidance. Chapter 4 introduces the applicable scope of Guidance. Chapter 5 introduces the general requirements of international multi-center clinical trials of drugs in China. Chapter 6 elaborates a series of scientific issues that Guidance requires sponsors to be considered. Chapter 7 elaborates a series of compliance issues that Guidance requires sponsors to be considered. Chapter 8 elaborates the clinical trial protocol amendment. Chapter 9 introduces the requirements for using the data from international multi-center clinical trials to support the application for drug registration in China. Chapter 10 introduces the authority, objects, contents, scope and requirements of Chinese drug regulatory authorities implementing inspection and verification on clinical trial sites. Chapter 11 provides a comprehensively and thoroughly practical guidance for application and approval of pharmaceutical international multi-center clinical trials in China, from the knowledge preparation and operation preparation before application, the specific regulations on overseas applicant and application, to the practical operation of application for approval as well as registration and information disclosure of international multi-center clinical trials of drugs in China to smoothly navigate complex regulatory requirements step by step. Chapter 12 provides a comprehensively comparative analysis to reveal the opportunities and challenges of international multi-center clinical trials of drugs in China, and to tell overseas and multinational pharmaceutical companies how to respond challenges. Chapter 13 Appendices provide a complete set of full text in English of application forms involved in application for approval of pharmaceutical international multi-center clinical trials in China, which include “Application Form of Drug Registration”, “Application Form for Special Examination and Approval of New Drug Registration”, and “Application Form for Communication of Special Examination and Approval of New Drug Registration”.
Buy a copy of this research report at https://www.themarketreports.com/report/buy-now/1255?license=Single_User_Price
About ‘The Market Reports’
We at, The Market Reports aiming to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are deali ng with so many Publishers, we can actually give you what suits best in accordance to your requirements.
  
 
 

Contact Information

  • Name: Mustafa Manawarwala

    Company: The Market Reports

    Telphone: -- , -

    Address: Contact us at
    The Market Reports
    +1-631-407-1315 (US)
    +91-750-729-1479 (India)
    Email Id : support@themarketreports.com

    Email: web@themarketreports.com